Jacobs & Co. CA Has $266,000 Holdings in Novartis AG (NYSE:NVS)

Jacobs & Co. CA decreased its position in shares of Novartis AG (NYSE:NVSFree Report) by 7.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,750 shares of the company’s stock after selling 225 shares during the quarter. Jacobs & Co. CA’s holdings in Novartis were worth $266,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Frazier Financial Advisors LLC bought a new stake in shares of Novartis during the fourth quarter worth about $26,000. Richardson Financial Services Inc. acquired a new stake in Novartis during the 4th quarter worth approximately $26,000. Operose Advisors LLC bought a new stake in Novartis during the 3rd quarter worth approximately $28,000. Planned Solutions Inc. acquired a new position in Novartis in the 4th quarter valued at approximately $31,000. Finally, AdvisorNet Financial Inc raised its stake in shares of Novartis by 480.0% during the fourth quarter. AdvisorNet Financial Inc now owns 348 shares of the company’s stock valued at $35,000 after acquiring an additional 288 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Analyst Ratings Changes

NVS has been the subject of a number of recent research reports. The Goldman Sachs Group began coverage on Novartis in a report on Thursday, May 30th. They issued a “buy” rating and a $120.00 price objective for the company. BMO Capital Markets upped their price target on Novartis from $114.00 to $116.00 and gave the company a “market perform” rating in a research report on Wednesday, April 24th. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novartis presently has an average rating of “Moderate Buy” and an average target price of $116.67.

View Our Latest Stock Report on NVS

Novartis Trading Up 0.1 %

Shares of NYSE:NVS traded up $0.06 during trading on Tuesday, reaching $107.01. The stock had a trading volume of 222,954 shares, compared to its average volume of 1,471,362. Novartis AG has a 52 week low of $92.19 and a 52 week high of $108.78. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.71 and a current ratio of 0.90. The firm’s fifty day moving average is $101.13 and its 200 day moving average is $100.97. The stock has a market cap of $218.73 billion, a price-to-earnings ratio of 14.48, a P/E/G ratio of 1.62 and a beta of 0.58.

Novartis (NYSE:NVSGet Free Report) last issued its quarterly earnings results on Tuesday, April 23rd. The company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.73 by $0.07. Novartis had a net margin of 31.33% and a return on equity of 32.15%. The business had revenue of $11.83 billion for the quarter, compared to analysts’ expectations of $11.50 billion. As a group, equities analysts forecast that Novartis AG will post 7.27 EPS for the current fiscal year.

About Novartis

(Free Report)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Further Reading

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.